Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Sanofi (OtherSNYNF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ultragenyx Pharmaceutical (RARE) and Sanofi (SNYNF).
Ultragenyx Pharmaceutical (RARE)
Bank of America Securities analyst Tazeen Ahmad reiterated a Hold rating on Ultragenyx Pharmaceutical yesterday and set a price target of $20.00. The company’s shares closed last Tuesday at $16.63.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
Ultragenyx Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $25.79, representing a 56.1% upside. In a report issued on October 28, TipRanks – DeepSeek also upgraded the stock to Hold with a $16.00 price target.
See the top stocks recommended by analysts >>
Sanofi (SNYNF)
Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi today and set a price target of EUR105.00. The company’s shares closed last Tuesday at $90.80, close to its 52-week low of $88.90.
According to TipRanks.com, Hector is a 4-star analyst with an average return of
Sanofi has an analyst consensus of Moderate Buy, with a price target consensus of $105.03, which is a 15.4% upside from current levels. In a report issued on October 21, TipRanks – DeepSeek also upgraded the stock to Buy with a EUR81.00 price target.
Read More on RARE:
Disclaimer & DisclosureReport an Issue
- Ultragenyx Announces Workforce Reduction and Strategic Restructuring
- Ultragenyx reports Q3 EPS ($1.16), consensus (75c)
- Ultragenyx anticipates achieving full-year GAAP profitability in 2027
- Ultragenyx’s GTX-102 Angelman Syndrome Study Terminated: What Investors Should Know
- RARE Earnings this Week: How Will it Perform?
